Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Cost of product revenue | 200 | — |
| Research and development | 100,081 | 76,240 |
| Selling, general and administrative | 50,831 | 35,526 |
| Total operating expenses | 151,112 | 111,766 |
| Loss from operations | (140,378) | (111,405) |
| Other income (expense): | ||
| Interest income | 12,664 | 14,834 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's G&A?
- Crinetics Pharmaceuticals (CRNX) reported G&A of $50.83M in Q1 2026.
- How has Crinetics Pharmaceuticals's G&A changed year-over-year?
- Crinetics Pharmaceuticals's G&A increased by 43.1% year-over-year, from $35.53M to $50.83M.
- What is the long-term trend for Crinetics Pharmaceuticals's G&A?
- Over 3 years (2021 to 2024), Crinetics Pharmaceuticals's G&A has grown at a 59.6% compound annual growth rate (CAGR), from $24.53M to $99.74M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Crinetics Pharmaceuticals's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude